Understanding Elephantiasis: Lymphatic Filariasis Guide

Explore the causes, symptoms, and treatment of Elephantiasis (Lymphatic Filariasis). Learn about the Wuchereria bancrofti parasite and global elimination efforts.

#elephantiasis#lymphatic-filariasis#infectious-disease#tropical-medicine#wuchereria-bancrofti#parasitology#global-health

Watch
Pitch

INFECTIOUS DISEASE REPORT

ELEPHANTIASIS

Lymphatic Filariasis

A Neglected Tropical Disease caused by parasitic worms

Parasite

Tropical

Preventable

Wuchereria bancrofti microfilaria (×400)

Biology Infectious Disease Unit

Made by

01 — NAME OF DISEASE

Common Name

ELEPHANTIASIS

From Greek: 'elephas' (ἐλέφας) meaning elephant — referring to the thick, rough skin resembling elephant hide

Also called: Lymphedema, Tropical Elephantiasis

Scientific Name

Lymphatic Filariasis

Named after the filarial worms (Filarioidea) that infect the lymphatic system

ICD-10 Code: B74.0

The word 'Elephantiasis' was first used to describe the dramatic swelling and skin thickening that resembles an elephant's leg.

Made by

02 — THE PATHOGEN

Scientific Name

Wuchereria bancrofti

Named after Otto Wucherer & Joseph Bancroft, who discovered the worm in the 1800s

Also causes: Brugia malayi, Brugia timori (less common)

Type of Pathogen

Parasitic Nematode

(Roundworm)

Kingdom Animalia

Phylum Nematoda

Class Chromadorea

Family Onchocercidae

Size Range

Microfilaria: 280 μm long × 25 μm wide

Male adult worm: 40 mm long × 100 μm wide

Female adult worm: 60–100 mm long × 300 μm wide

L1 larvae: 124–250 μm

Female is 3× larger than male!

Wuchereria bancrofti accounts for ~90% of all lymphatic filariasis cases globally. It is transmitted by mosquito bite.

Made by

03 — PATHOGEN STRUCTURE

Cephalic region (head)

Neck constriction

Body cavity w/ scattered dark nuclei

Reproductive organs

Tail tip (no nuclei)

♀ FEMALE

♂ MALE

Relative Size

Female

8-10 cm

Male

4 cm

External Structure

Smooth, slender cylindrical body that is white/translucent
Characterized by rounded ends
Short cephalic (head) region connected by a neck constriction

Internal Structure

Scattered dark nuclei in body cavity & primitive digestive tract
Male: 15 pairs of caudal papillae (sensory organs)
Female: Elaborate reproductive tract continuously producing microfilariae

Microfilaria Stage

Microscopic size: 280 μm length × 25 μm width
Colorless and highly transparent
Contains a primitive gut, nerve ring, and a retained egg membrane (sheath)

Adult worms live coiled together inside lymphatic vessels for up to 7 years!

Made by

04 — HISTORICAL TIMELINE

~600 BCE

Ancient Records

Hindu texts describe elephantiasis-like swelling. Ancient Egyptians also recorded the disease.

1863

Discovery

Jean-Nicolas Demarquay discovers microfilaria in lymphatic fluid. Timothy Lewis finds microfilaria in blood.

1877

Worm Identified

Joseph Bancroft discovers adult Wuchereria bancrofti worm in Australia.

1878

Mosquito Link

Patrick Manson proves mosquitoes transmit the parasite — first insect-disease transmission proven in history!

1900s

Naming

Disease officially named Wuchereria bancrofti after Wucherer & Bancroft.

1947

DEC Treatment

Diethylcarbamazine (DEC) developed as first effective drug treatment.

2000

WHO GPELF

Global Programme to Eliminate Lymphatic Filariasis launched. Mass drug administration begins worldwide.

2024

Progress

21 countries achieve elimination status. 69% reduction in global burden.

Patrick Manson's 1878 discovery was a landmark moment — it was the FIRST proof that insects can transmit human disease.

Made by

05 — TRANSMISSION

Infected Person

Human host has microfilariae in bloodstream.

➞

Mosquito Bite

Female mosquito bites infected person and ingests microfilariae.

➞

Inside Mosquito

Microfilariae develop into infective L3 larvae over 10–14 days.

➞

New Human Host

Infected mosquito bites a new person; L3 larvae mature over 6–12 months.

➞

Main Vector Mosquitoes

Culex quinquefasciatus (most common, 90%+)
Anopheles species
Aedes species

Note: ~70 mosquito species can transmit W. bancrofti.

How You CANNOT Catch It

NOT spread by: casual contact, touching, sharing food, coughing/sneezing.

Requires repeated mosquito bites in endemic areas.

You need MANY infected mosquito bites over time — a single bite rarely causes infection. Endemic regions: Africa, Asia, Pacific Islands.

Made by

06 — INCUBATION PERIOD & SYMPTOMS

6–12

MONTHS

Incubation Period

Time between mosquito bite and first symptoms

Microfilariae may circulate in blood for MONTHS before symptoms appear

Many people remain asymptomatic despite being infected

Adult worms take months to mature in lymphatic vessels

🔴

Acute Stage

Lymphangitis (inflamed lymph vessels)

Lymphadenitis (swollen lymph nodes)

Recurring fever and chills

Pain and tenderness

Elevated eosinophils in blood

🟢

Chronic Stage (years later)

Lymphedema — massive swelling of limbs

Elephantiasis — thickened, rough "elephant skin"

Hydrocele — fluid in scrotum (males)

Chyluria — milky white urine

Breast/genital swelling

Most infected people never show visible symptoms — but lymphatic damage occurs silently inside the body.

Made by

07 — RISK FACTORS & COMPLICATIONS

⚠️ RISK FACTORS

Living in endemic tropical/subtropical regions (Africa, Asia, Pacific)

High mosquito exposure — poor housing, no nets

💧

Lack of clean water & sanitation

Sleeping without mosquito protection

Long-term residence since childhood in endemic area

Limited access to healthcare/treatment

🚨 POTENTIAL COMPLICATIONS

Permanent Lymphedema

Irreversible swelling of limbs, causing lifelong disability

Elephantiasis

Gross enlargement of limbs/genitals; skin becomes thick, warty, darkened

Hydrocele

Accumulation of fluid around the testes; affects up to 25% of males in endemic areas

Secondary bacterial infections

Repeated skin infections due to damaged lymphatic defenses

Psychological & Social Impact

Stigma, depression, inability to work; major disability burden

Elephantiasis causes ~1.31 million DALYs (disability-adjusted life years) lost globally each year — it is a leading cause of permanent disability.

Made by

08 — TREATMENT & MANAGEMENT

DRUG OF CHOICE

Diethylcarbamazine (DEC)

• Kills BOTH microfilariae AND adult worms
• Microfilaricidal + Macrofilaricidal
• Most effective single drug
• Used since 1947
• NOT used where onchocerciasis is co-endemic

MICROFILARICIDE

Ivermectin

• Kills microfilariae only (not adult worms)
• Single-dose administration
• Rapid clearance of microfilariae
• Used in combination therapy
• Effective alternative to DEC

COMBINATION THERAPY

Albendazole

• Used in combination with DEC or Ivermectin
• Microfilaricidal effect
• Part of WHO Triple Drug Therapy (IDA)
• IDA = Ivermectin + DEC + Albendazole (most effective regimen)

Lymphedema Management

✓ Specialized lymphatic therapy ✓ Compression bandaging ✓ Hygiene care ✓ Elevation of affected limbs ✓ Gentle exercise

Surgical Options

Hydrocelectomy (fluid removal surgery)

Surgery for severe lymphedema cases

The WHO Triple Drug Therapy (IDA) — Ivermectin + DEC + Albendazole — is the MOST effective treatment and clears parasites faster than 2-drug regimens.

Made by

09 — VACCINATION & CONTROL PROGRAMS

⚠️

NO VACCINE EXISTS

There is currently no approved vaccine for Lymphatic Filariasis. Prevention relies on drug treatment and mosquito control.

WHO Global Programme (GPELF)

Est. 2000

•

Largest disease elimination program in history

•

Goal: Eliminate LF as public health problem by 2030

•

Strategy: Annual Mass Drug Administration (MDA)

•

Over 10 BILLION treatments delivered since 2000

•

72 endemic countries targeted

•

21 countries have already achieved elimination (2024)

Mass Drug Administration (MDA)

•

Entire at-risk population treated once or twice per year

•

Minimum 80% population coverage required

•

Drugs used: DEC + Albendazole OR Ivermectin + Albendazole

•

Reduces microfilariae in blood → breaks transmission cycle

•

Free distribution in endemic communities

❌

Vector (Mosquito) Control

•

Insecticide-treated bed nets (ITNs)

•

Indoor residual spraying (IRS)

•

DEET insect repellents

•

Eliminating standing water (breeding sites)

•

Community education programs

Countries no longer need MDA

924M

People free from required treatment

69%

Reduction in global burden achieved

Made by

10 — EPIDEMIOLOGY

~57 MILLION

People infected globally (2021)

1.31 MILLION

DALYs lost per year (disability burden)

72 COUNTRIES

Endemic nations worldwide

10+ BILLION

Treatments delivered since 2000

Endemic Regions: Sub-Saharan Africa, South Asia, Southeast Asia, Pacific Islands, Americas

Global Case Distribution

South Asia

61%

34.67 million cases

Southeast Asia

14%

7.88 million cases

Sub-Saharan Africa

12%

6.93 million cases

Rest of World

13%

7.52 million cases (est.)

Progress 2000–2024

69.2% reduction in people needing treatment. 21 countries eliminated the disease. 172 million people declared free in 2024 alone!

Mortality & Morbidity

Low mortality but HIGH morbidity. Leading cause of permanent disability in tropics. Major economic impact — affected people lose ~20% of working capacity.

Made by

11 — IMAGES OF THE PATHOGEN & DISEASE

Wuchereria bancrofti microfilaria under light microscopy (CDC)

Elephantiasis: severe lymphedema of the leg

Life Cycle of W. bancrofti

Culex quinquefasciatus — main vector mosquito

Human lymphatic system affected by LF

Made by

KEY TAKEAWAYS

🦟

Spread by mosquito bites — NOT person to person

🪱

Caused by Wuchereria bancrofti — a parasitic roundworm

⏱️

6–12 month incubation — silent damage inside body

💊

Treatable with DEC, Ivermectin & Albendazole (IDA)

🌍

~57 million infected — a Neglected Tropical Disease

✅

Eliminatable! 21 countries already disease-free (2024)

Elephantiasis is PREVENTABLE, TREATABLE & ELIMINATABLE — with the right tools and global commitment.

Sources: WHO, CDC, Global Burden of Disease Study 2021

Made by

DESIGNER-MADE
PRESENTATION,
GENERATED FROM
YOUR PROMPT

Create your own professional slide deck with real images, data charts, and unique design in under a minute.

Generate For Free